Share Price and Basic Stock Data
Last Updated: October 28, 2025, 4:07 pm
| PEG Ratio | -1.45 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Concord Biotech Ltd, operating in the pharmaceutical sector, reported a significant growth trajectory in its revenue, with sales rising from ₹713 Cr in March 2022 to ₹1,200 Cr in March 2025. This represents a compound annual growth rate (CAGR) of approximately 20.5%. The company recorded quarterly sales of ₹195 Cr in June 2023, which increased to ₹319 Cr by March 2024, showcasing a robust recovery post-pandemic. However, the subsequent quarter saw a decline to ₹216 Cr in June 2024, reflecting potential seasonality or market challenges. Despite this, the overall trend indicates strong demand for its products. The operating profit margin (OPM) fluctuated around 30% for the period, with peaks of 47% in March 2023 and 44% in March 2025, highlighting effective cost management and pricing strategies. With a diversified product portfolio, Concord Biotech is well-positioned to capitalize on the growing pharmaceutical market, which is projected to reach ₹5.6 trillion by 2025, according to the Indian Brand Equity Foundation.
Profitability and Efficiency Metrics
Concord Biotech’s profitability metrics reflect a healthy operational environment. The net profit stood at ₹373 Cr for March 2025, up from ₹238 Cr in March 2023, underscoring a strong recovery in earnings. The earnings per share (EPS) also demonstrated impressive growth, increasing from ₹22.76 in March 2023 to ₹35.65 in March 2025. The return on equity (ROE) for the company was reported at 21.4%, while the return on capital employed (ROCE) was a robust 28.4%, indicating effective utilization of shareholder funds. The interest coverage ratio (ICR) soared to an exceptional 1040.58x in March 2025, suggesting that the company’s earnings are more than sufficient to cover interest expenses, thereby minimizing financial risk. Despite a cash conversion cycle (CCC) of 310 days, which is relatively high, the company’s liquidity ratios, including a current ratio of 6.17, indicate a strong liquidity position, allowing it to comfortably meet short-term obligations.
Balance Sheet Strength and Financial Ratios
The financial health of Concord Biotech is reflected in its balance sheet, which shows a notable increase in reserves, rising from ₹1,098 Cr in March 2022 to ₹1,802 Cr in March 2025, while borrowings remain negligible at ₹3 Cr, indicating a debt-free status. The total liabilities stood at ₹2,034 Cr, supported by total assets of the same magnitude, ensuring a solid equity base. The debt-to-equity ratio is effectively at 0.00, reflecting no reliance on external debt for funding operations. The price-to-book value (P/BV) ratio was reported at 9.67x, which may be considered high compared to sector norms, suggesting that the market has high expectations for future growth. Additionally, the company’s strong liquidity ratios, including a quick ratio of 4.87, further affirm its ability to manage short-term liabilities. These metrics position Concord Biotech favorably within the industry, particularly in a capital-intensive sector like pharmaceuticals.
Shareholding Pattern and Investor Confidence
Concord Biotech’s shareholding structure reveals a balanced distribution among promoters, institutional investors, and the public. Promoters hold 44.08% of the shares, indicating strong control and commitment to the company’s long-term vision. Foreign institutional investors (FIIs) have gradually increased their stake from 7.30% in September 2023 to 9.10% by June 2025, suggesting growing confidence in the firm. Domestic institutional investors (DIIs) have shown a stable presence, holding around 8.85% as of June 2025. The public’s shareholding has slightly decreased to 37.94%, reflecting a potential shift towards institutional ownership which is often viewed as a positive sign by the market. The total number of shareholders stood at 82,045 in June 2025, indicating a stable retail investor base. This diversified shareholding pattern is likely to enhance corporate governance and attract further investments.
Outlook, Risks, and Final Insight
If margins sustain amidst increasing competition and regulatory challenges, Concord Biotech could leverage its robust operational framework to enhance profitability further. However, risks persist, including potential fluctuations in raw material costs and changing regulatory environments that could impact margins. Additionally, the high cash conversion cycle poses a challenge to operational efficiency, which management may need to address. On the positive side, the company’s strong liquidity position and absence of debt provide a buffer against economic downturns. If the company continues to innovate and expand its product portfolio, it is likely to capture a more significant market share in the growing pharmaceutical sector. Overall, Concord Biotech’s fundamentals remain strong, positioning it well for future growth, provided it navigates the inherent risks effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Concord Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,012 Cr. | 460 | 480/192 | 112 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.8 Cr. | 22.4 | 29.1/17.0 | 34.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,781.40 Cr | 1,180.67 | 50.44 | 194.36 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 159 | 241 | 273 | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 |
| Expenses | 116 | 121 | 129 | 144 | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 |
| Operating Profit | 65 | 38 | 112 | 129 | 72 | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 |
| OPM % | 36% | 24% | 46% | 47% | 37% | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% |
| Other Income | 8 | 6 | 9 | 12 | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 14 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 |
| Profit before tax | 58 | 30 | 106 | 126 | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 |
| Tax % | 26% | 26% | 26% | 26% | 25% | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% |
| Net Profit | 43 | 22 | 79 | 94 | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 |
| EPS in Rs | 45.32 | 2.14 | 7.56 | 8.94 | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 |
Last Updated: August 19, 2025, 8:50 pm
Below is a detailed analysis of the quarterly data for Concord Biotech Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 204.00 Cr.. The value appears to be declining and may need further review. It has decreased from 430.00 Cr. (Mar 2025) to 204.00 Cr., marking a decrease of 226.00 Cr..
- For Expenses, as of Jun 2025, the value is 143.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 239.00 Cr. (Mar 2025) to 143.00 Cr., marking a decrease of 96.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 61.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Mar 2025) to 61.00 Cr., marking a decrease of 129.00 Cr..
- For OPM %, as of Jun 2025, the value is 30.00%. The value appears to be declining and may need further review. It has decreased from 44.00% (Mar 2025) to 30.00%, marking a decrease of 14.00%.
- For Other Income, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 185.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 128.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 43.00 Cr.. The value appears to be declining and may need further review. It has decreased from 142.00 Cr. (Mar 2025) to 43.00 Cr., marking a decrease of 99.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.07. The value appears to be declining and may need further review. It has decreased from 13.57 (Mar 2025) to 4.07, marking a decrease of 9.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:36 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,200 | 1,188 |
| Expenses | 195 | 256 | 308 | 289 | 439 | 509 | 585 | 693 | 702 |
| Operating Profit | 145 | 180 | 205 | 328 | 274 | 344 | 432 | 507 | 486 |
| OPM % | 43% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 41% |
| Other Income | 18 | 17 | 31 | 14 | 23 | 35 | 34 | 44 | 48 |
| Interest | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 0 |
| Depreciation | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 59 |
| Profit before tax | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 496 | 475 |
| Tax % | 30% | 33% | 21% | 25% | 26% | 26% | 26% | 25% | |
| Net Profit | 100 | 118 | 169 | 235 | 179 | 238 | 305 | 373 | 357 |
| EPS in Rs | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 29.13 | 35.65 | 34.15 |
| Dividend Payout % | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 18.00% | 43.22% | 39.05% | -23.83% | 32.96% | 28.15% | 22.30% |
| Change in YoY Net Profit Growth (%) | 0.00% | 25.22% | -4.17% | -62.88% | 56.79% | -4.81% | -5.86% |
Concord Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: September 10, 2025, 3:24 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,515 | 1,802 |
| Borrowings | 22 | 9 | 52 | 89 | 62 | 32 | 10 | 3 |
| Other Liabilities | 69 | 72 | 118 | 94 | 144 | 191 | 164 | 219 |
| Total Liabilities | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 |
| Fixed Assets | 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 |
| CWIP | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 |
| Investments | 151 | 229 | 199 | 142 | 74 | 138 | 244 | 335 |
| Other Assets | 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 |
| Total Assets | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 |
Below is a detailed analysis of the balance sheet data for Concord Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,802.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,515.00 Cr. (Mar 2024) to 1,802.00 Cr., marking an increase of 287.00 Cr..
- For Borrowings, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 10.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 7.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 219.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 164.00 Cr. (Mar 2024) to 219.00 Cr., marking an increase of 55.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,034.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,699.00 Cr. (Mar 2024) to 2,034.00 Cr., marking an increase of 335.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 795.00 Cr.. The value appears strong and on an upward trend. It has increased from 575.00 Cr. (Mar 2024) to 795.00 Cr., marking an increase of 220.00 Cr..
- For CWIP, as of Mar 2025, the value is 51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 211.00 Cr. (Mar 2024) to 51.00 Cr., marking a decrease of 160.00 Cr..
- For Investments, as of Mar 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2024) to 335.00 Cr., marking an increase of 91.00 Cr..
- For Other Assets, as of Mar 2025, the value is 854.00 Cr.. The value appears strong and on an upward trend. It has increased from 668.00 Cr. (Mar 2024) to 854.00 Cr., marking an increase of 186.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,034.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,699.00 Cr. (Mar 2024) to 2,034.00 Cr., marking an increase of 335.00 Cr..
Notably, the Reserves (1,802.00 Cr.) exceed the Borrowings (3.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 123.00 | 171.00 | 153.00 | 239.00 | 212.00 | 312.00 | 422.00 | 504.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 236 | 133 | 131 | 105 | 119 | 117 | 125 | 159 |
| Inventory Days | 381 | 310 | 312 | 503 | 434 | 430 | 331 | 286 |
| Days Payable | 210 | 112 | 201 | 152 | 185 | 190 | 150 | 135 |
| Cash Conversion Cycle | 407 | 331 | 242 | 456 | 368 | 357 | 306 | 310 |
| Working Capital Days | 275 | 186 | 159 | 177 | 163 | 153 | 166 | 193 |
| ROCE % | 27% | 25% | 32% | 21% | 26% | 28% | 28% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Small Cap Fund - Regular Plan | 853,962 | 0.88 | 140.71 | 853,962 | 2025-04-22 17:25:13 | 0% |
| SBI Healthcare Opportunities Fund | 720,000 | 3.02 | 118.63 | N/A | N/A | N/A |
| Baroda BNP Paribas Multi Cap Fund | 252,816 | 1.41 | 41.66 | N/A | N/A | N/A |
| Invesco India Multicap Fund | 226,042 | 0.91 | 37.24 | 169,680 | 2025-10-15 02:40:18 | 33.22% |
| DSP Small Cap Fund | 186,674 | 0.19 | 30.76 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 111,738 | 0.23 | 18.41 | N/A | N/A | N/A |
| Union Small Cap Fund | 70,000 | 0.67 | 11.53 | N/A | N/A | N/A |
| Baroda BNP Paribas ELSS Tax Saver Fund | 58,700 | 1.08 | 9.67 | N/A | N/A | N/A |
| Invesco India Aggressive Hybrid Fund | 42,148 | 0.88 | 6.94 | N/A | N/A | N/A |
| Union ELSS Tax Saver Fund | 30,000 | 0.55 | 4.94 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 10.00 |
| Basic EPS (Rs.) | 35.52 | 29.45 | 22.95 | 16.72 |
| Diluted EPS (Rs.) | 35.52 | 29.45 | 22.95 | 16.72 |
| Cash EPS (Rs.) | 40.85 | 34.25 | 27.93 | 240.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 173.27 | 145.93 | 123.31 | 1159.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 173.27 | 145.93 | 123.31 | 1159.99 |
| Revenue From Operations / Share (Rs.) | 114.71 | 97.21 | 81.55 | 749.62 |
| PBDIT / Share (Rs.) | 52.65 | 44.48 | 36.19 | 311.96 |
| PBIT / Share (Rs.) | 47.45 | 39.36 | 31.02 | 259.33 |
| PBT / Share (Rs.) | 47.40 | 39.11 | 30.59 | 253.57 |
| Net Profit / Share (Rs.) | 35.65 | 29.13 | 22.76 | 187.76 |
| NP After MI And SOA / Share (Rs.) | 35.52 | 29.45 | 22.95 | 183.93 |
| PBDIT Margin (%) | 45.89 | 45.75 | 44.37 | 41.61 |
| PBIT Margin (%) | 41.36 | 40.48 | 38.04 | 34.59 |
| PBT Margin (%) | 41.31 | 40.23 | 37.51 | 33.82 |
| Net Profit Margin (%) | 31.07 | 29.96 | 27.91 | 25.04 |
| NP After MI And SOA Margin (%) | 30.96 | 30.29 | 28.14 | 24.53 |
| Return on Networth / Equity (%) | 20.50 | 20.18 | 18.61 | 15.85 |
| Return on Capital Employeed (%) | 26.82 | 26.41 | 24.54 | 21.30 |
| Return On Assets (%) | 18.26 | 18.11 | 15.85 | 13.32 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.02 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.02 | 0.05 |
| Asset Turnover Ratio (%) | 0.64 | 0.63 | 0.60 | 0.00 |
| Current Ratio (X) | 6.17 | 6.30 | 3.79 | 4.08 |
| Quick Ratio (X) | 4.87 | 4.84 | 2.69 | 2.82 |
| Inventory Turnover Ratio (X) | 5.36 | 0.87 | 0.82 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 24.63 | 23.19 | 22.31 | 40.31 |
| Dividend Payout Ratio (CP) (%) | 21.48 | 19.75 | 18.21 | 31.34 |
| Earning Retention Ratio (%) | 75.37 | 76.81 | 77.69 | 59.69 |
| Cash Earning Retention Ratio (%) | 78.52 | 80.25 | 81.79 | 68.66 |
| Interest Coverage Ratio (X) | 1040.58 | 182.35 | 83.94 | 54.11 |
| Interest Coverage Ratio (Post Tax) (X) | 705.64 | 120.41 | 53.80 | 33.56 |
| Enterprise Value (Cr.) | 17536.50 | 15881.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 14.61 | 15.62 | 0.00 | 0.00 |
| EV / EBITDA (X) | 31.84 | 34.13 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 14.61 | 15.66 | 0.00 | 0.00 |
| Retention Ratios (%) | 75.36 | 76.80 | 77.68 | 59.68 |
| Price / BV (X) | 9.67 | 10.43 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 14.61 | 15.66 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Concord Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
- For Diluted EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
- For Cash EPS (Rs.), as of Mar 25, the value is 40.85. This value is within the healthy range. It has increased from 34.25 (Mar 24) to 40.85, marking an increase of 6.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.71. It has increased from 97.21 (Mar 24) to 114.71, marking an increase of 17.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 52.65. This value is within the healthy range. It has increased from 44.48 (Mar 24) to 52.65, marking an increase of 8.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 47.45. This value is within the healthy range. It has increased from 39.36 (Mar 24) to 47.45, marking an increase of 8.09.
- For PBT / Share (Rs.), as of Mar 25, the value is 47.40. This value is within the healthy range. It has increased from 39.11 (Mar 24) to 47.40, marking an increase of 8.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 35.65. This value is within the healthy range. It has increased from 29.13 (Mar 24) to 35.65, marking an increase of 6.52.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
- For PBDIT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.75 (Mar 24) to 45.89, marking an increase of 0.14.
- For PBIT Margin (%), as of Mar 25, the value is 41.36. This value exceeds the healthy maximum of 20. It has increased from 40.48 (Mar 24) to 41.36, marking an increase of 0.88.
- For PBT Margin (%), as of Mar 25, the value is 41.31. This value is within the healthy range. It has increased from 40.23 (Mar 24) to 41.31, marking an increase of 1.08.
- For Net Profit Margin (%), as of Mar 25, the value is 31.07. This value exceeds the healthy maximum of 10. It has increased from 29.96 (Mar 24) to 31.07, marking an increase of 1.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 30.96. This value exceeds the healthy maximum of 20. It has increased from 30.29 (Mar 24) to 30.96, marking an increase of 0.67.
- For Return on Networth / Equity (%), as of Mar 25, the value is 20.50. This value is within the healthy range. It has increased from 20.18 (Mar 24) to 20.50, marking an increase of 0.32.
- For Return on Capital Employeed (%), as of Mar 25, the value is 26.82. This value is within the healthy range. It has increased from 26.41 (Mar 24) to 26.82, marking an increase of 0.41.
- For Return On Assets (%), as of Mar 25, the value is 18.26. This value is within the healthy range. It has increased from 18.11 (Mar 24) to 18.26, marking an increase of 0.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has decreased from 6.30 (Mar 24) to 6.17, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 4.87. This value exceeds the healthy maximum of 2. It has increased from 4.84 (Mar 24) to 4.87, marking an increase of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.36. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 5.36, marking an increase of 4.49.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.19 (Mar 24) to 24.63, marking an increase of 1.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 21.48. This value is within the healthy range. It has increased from 19.75 (Mar 24) to 21.48, marking an increase of 1.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 75.37. This value exceeds the healthy maximum of 70. It has decreased from 76.81 (Mar 24) to 75.37, marking a decrease of 1.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 78.52. This value exceeds the healthy maximum of 70. It has decreased from 80.25 (Mar 24) to 78.52, marking a decrease of 1.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,040.58. This value is within the healthy range. It has increased from 182.35 (Mar 24) to 1,040.58, marking an increase of 858.23.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 705.64. This value is within the healthy range. It has increased from 120.41 (Mar 24) to 705.64, marking an increase of 585.23.
- For Enterprise Value (Cr.), as of Mar 25, the value is 17,536.50. It has increased from 15,881.24 (Mar 24) to 17,536.50, marking an increase of 1,655.26.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.62 (Mar 24) to 14.61, marking a decrease of 1.01.
- For EV / EBITDA (X), as of Mar 25, the value is 31.84. This value exceeds the healthy maximum of 15. It has decreased from 34.13 (Mar 24) to 31.84, marking a decrease of 2.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
- For Retention Ratios (%), as of Mar 25, the value is 75.36. This value exceeds the healthy maximum of 70. It has decreased from 76.80 (Mar 24) to 75.36, marking a decrease of 1.44.
- For Price / BV (X), as of Mar 25, the value is 9.67. This value exceeds the healthy maximum of 3. It has decreased from 10.43 (Mar 24) to 9.67, marking a decrease of 0.76.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Biotech Ltd:
- Net Profit Margin: 31.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 26.82% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 20.5% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 705.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.87
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 42 (Industry average Stock P/E: 41.89)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 31.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 1482-1486, Trasad Road, Ahmedabad Gujarat 382225 | complianceofficer@concordbiotech.com http://www.concordbiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Vaid | Chairman & Managing Director |
| Mr. Ankur Vaid | Joint Managing Director & CEO |
| Mr. Ravi Kapoor | Non Executive Director |
| Mr. Rajiv Ambrish Agarwal | Non Executive Director |
| Mrs. Bharti Khanna | Independent Director |
| Mr. Amitabh Thakore | Independent Director |
| Mr. Arvind Agarwal | Independent Director |
| Mr. Jayaram Easwaran | Independent Director |
| Mr. Mandayam Chakravarthy Sriraman | Independent Director |
FAQ
What is the intrinsic value of Concord Biotech Ltd?
Concord Biotech Ltd's intrinsic value (as of 28 October 2025) is 1253.02 which is 12.50% lower the current market price of 1,432.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 14,983 Cr. market cap, FY2025-2026 high/low of 2,452/1,345, reserves of ₹1,802 Cr, and liabilities of 2,034 Cr.
What is the Market Cap of Concord Biotech Ltd?
The Market Cap of Concord Biotech Ltd is 14,983 Cr..
What is the current Stock Price of Concord Biotech Ltd as on 28 October 2025?
The current stock price of Concord Biotech Ltd as on 28 October 2025 is 1,432.
What is the High / Low of Concord Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Concord Biotech Ltd stocks is 2,452/1,345.
What is the Stock P/E of Concord Biotech Ltd?
The Stock P/E of Concord Biotech Ltd is 42.0.
What is the Book Value of Concord Biotech Ltd?
The Book Value of Concord Biotech Ltd is 173.
What is the Dividend Yield of Concord Biotech Ltd?
The Dividend Yield of Concord Biotech Ltd is 0.73 %.
What is the ROCE of Concord Biotech Ltd?
The ROCE of Concord Biotech Ltd is 28.4 %.
What is the ROE of Concord Biotech Ltd?
The ROE of Concord Biotech Ltd is 21.4 %.
What is the Face Value of Concord Biotech Ltd?
The Face Value of Concord Biotech Ltd is 1.00.